Speaker
Summary
In recent years, the successful development and commercialization of radiopharmaceuticals such as Lutathera and Pluvicto have led to a sharp increase in global demand for medical radioisotopes. Consequently, the stable supply of beta-emitting isotopes such as Lutetium-177 and alpha-emitters such as Actinium-225 has become increasingly critical, driving significant investments from both governments and major pharmaceutical suppliers. Research reactors play a pivotal role as essential infrastructure for the production of therapeutic and diagnostic radioisotopes. This presentation will provide an overview of the current construction status of Korea’s new research reactor and outline a roadmap for the supply of medical radioisotopes utilizing this facility.
| Are you interested/eligible for the Young Session? | No, I am not eligible |
|---|
